WHICH CAN SAVE YOU FROM A CYSTOSCOPY IF IT SHOWS THAT YOUR RISK OF BLADDER CANCER IS VERY LOW OR VERY HIGH, AND IT PUSHES YOU MORE TOWARDS MORE SCREENING AND MORE SCOPES IN TERMS OF TREATMENT ...

Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical ...

Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 125.3 million in the first quarter of 2025 (Q1 2024: NOK ...

Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research ...

Including patients, who demonstrated an Indeterminate Response ("IR") (negative cystoscopy and positive or suspicious ... represents a significant opportunity for an advancement in bladder cancer ...

A flexible cystoscopy confirmed the tumors seen on the CT urogram ... This includes: Dr. Packiam emphasized that contemporary non muscle invasive bladder cancer outcomes are improving, with historic ...

Subsequent cystoscopy showed raised red areas on the posterior wall ... Dr. O’Donnell’s group published their long term gemcitabine + docetaxel for BCG non muscle invasive bladder cancer in 2023. 4 ...

Endometriosis is often misdiagnosed or dismissed as "just bad cramps," leading to delays in treatment. Many women suffer for ...

Join leading experts to discuss how we are ushering in a new era in bladder cancer care on May 28 virtually. Register now.

AstraZeneca aims to widen the pool of bladder cancer patients who can be treated with its PD-L1 inhibitor Imfinzi after the ...

Bladder preservation for bladder cancer requires balancing clinical factors and patient health with a personalized treatment ...